Transepithelial versus epithelium-off corneal crosslinking for corneal ectasia

J Cataract Refract Surg. 2018 Dec;44(12):1507-1516. doi: 10.1016/j.jcrs.2018.08.021. Epub 2018 Oct 9.

Abstract

This review compared the clinical results of transepithelial corneal crosslinking (CXL) to epithelium-off (epi-off) CXL in progressive corneal ectasia using a metaanalysis. The Cochrane databases and Medline were searched for randomized controlled trials (RCTs). Seven RCTs involving 505 eyes that met the eligibility criteria were identified. The epi-off CXL group showed significantly better outcomes in postoperative changes in maximum keratometry (K) during 1-year observation periods. Transepithelial CXL resulted in significantly greater post-treatment central corneal thickness and best spectacle-corrected visual acuity (BSCVA). The presence of a postoperative demarcation line was significantly more frequent after epi-off CXL than that after transepithelial CXL. No statistically significant difference was found between other parameters. Although patients in the transepithelial CXL group demonstrated a greater improvement in BSCVA compared with patients in the epi-off CXL group at the 1 year follow-up, transepithelial CXL had less impact on halting progressive corneal ectasia in terms of maximum K than epi-off CXL.

Publication types

  • Review

MeSH terms

  • Collagen / therapeutic use*
  • Corneal Diseases / drug therapy*
  • Corneal Diseases / pathology
  • Corneal Topography / methods*
  • Cross-Linking Reagents / therapeutic use*
  • Dilatation, Pathologic / drug therapy
  • Dilatation, Pathologic / pathology
  • Epithelium, Corneal / drug effects
  • Epithelium, Corneal / pathology*
  • Humans
  • Photochemotherapy / methods*
  • Photosensitizing Agents / therapeutic use
  • Riboflavin / therapeutic use*

Substances

  • Cross-Linking Reagents
  • Photosensitizing Agents
  • Collagen
  • Riboflavin